fingolimod hydrochloride has been researched along with Apoplexy in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 16 (69.57) | 24.3611 |
| 2020's | 7 (30.43) | 2.80 |
| Authors | Studies |
|---|---|
| Fu, Y; Li, S; Lin, K; Lv, A; Tian, L; Wang, Z; Yan, Y; Zhao, W | 1 |
| Bai, P; Jiang, F; Li, M; Li, N; Liang, Z; Liu, B; Wang, M; Wang, P; Yao, Y; Yuan, J; Zhao, C; Zhen, J; Zhu, R | 1 |
| Li, F; Li, Y; Ling, L; Zhang, W | 1 |
| Arai, K; Esposito, E; Lee, J; Li, W; Lizasoain, I; Lo, EH; Mandeville, ET; Mandeville, JB; Moro, MÁ; Nakano, T; Park, JH; Quinto-Alemany, D; Waeber, C; Zhang, F | 1 |
| Houkin, K; Kawabori, M; Wang, Z | 1 |
| Bar-Klein, G; Friedman, A; Hameed, MQ; Jozwiak, S; Kaminski, RM; Klein, P; Klitgaard, H; Koepp, M; Löscher, W; Prince, DA; Rotenberg, A; Twyman, R; Vezzani, A; Wong, M | 1 |
| Bayat, M; Haghani, M; Naseh, M; Rafati, A; Vatanparast, J | 1 |
| Campbell, B; Lin, L; Lou, M; Shi, FD; Zhang, M; Zhang, R; Zhang, S; Zhou, Y | 1 |
| Ducruet, AF; Fu, Y; Gonzales, RJ; Huang, D; Liu, Q; Lou, M; Sheth, KN; Shi, FD; Shi, K; Su, L; Tian, DC; Waters, MF; Yang, X; Yao, J; Zhang, M; Zhang, S; Zhu, Z | 1 |
| Hua, L; Jing, Z; Liantao, Z; Lingling, L | 1 |
| Brait, VH; Chamorro, A; Gallizioli, M; Justicia, C; Meissner, A; Miró-Mur, F; Planas, AM; Salas-Perdomo, A; Urra, X | 1 |
| Brunkhorst, R; Derouiche, A; Ferreirós, N; Foerch, C; Kanaan, N; Koch, A; Mirceska, A; Mittelbronn, M; Pfeilschifter, J; Pfeilschifter, W; Steinmetz, H; Zeiner, P | 1 |
| Brede, M; Deppermann, C; Göb, E; Göbel, K; Herrmann, AM; Kleinschnitz, C; Kraft, P; Lorenz, K; Meuth, SG; Nieswandt, B; Pfeilschifter, W; Schuhmann, MK; Stoll, G; Thielmann, I | 1 |
| Fu, Y; Han, W; Hao, J; Li, YJ; Liu, Q; Ren, L; Shi, FD; Sun, N; Xue, R; Yan, Y; Yu, C; Zhang, N | 1 |
| Chang, G; Dong, Y; Fu, Y; Han, W; Huang, D; Liu, Q; Shi, FD; Sun, N; Tian, D; Xu, X; Zhu, Z | 1 |
| Choi, JW; Chun, J; Han, JE; Jeon, S; Moon, E; Ryu, JH | 1 |
| Fluri, F; Kleinschnitz, C; Krstic, M; Schuhmann, MK | 1 |
| Hasegawa, Y; Rolland, W; Sozen, T; Suzuki, H; Zhang, JH | 1 |
| Czech, B; Neumann-Haefelin, T; Pfeilschifter, W | 1 |
| Alsharif, N; Brinkmann, V; Guo, S; Hwang, SK; Kim, HH; Liao, JK; Lo, EH; Qin, T; Shin, HK; Waeber, C; Wei, Y; Yemisci, M; Yung, LM | 1 |
| Chabwine, JN; Démonet, JF; du Pasquier, RA; Hirt, L; Kuntzer, T; Michel, P; Rossetti, AR; Schluep, M; Vingerhoets, FG | 1 |
| Furberg, CD; Moore, TJ | 1 |
| Liu, J; Liu, M; Tao, W; Zhang, C | 1 |
6 review(s) available for fingolimod hydrochloride and Apoplexy
| Article | Year |
|---|---|
The efficacy and safety of fingolimod plus standardized treatment versus standardized treatment alone for acute ischemic stroke: A systematic review and meta-analysis.
Topics: Fingolimod Hydrochloride; Humans; Immunotherapy; Ischemic Stroke; Stroke | 2022 |
Sphingosine-1-phosphate receptor modulators in stroke treatment.
Topics: Animals; Fingolimod Hydrochloride; Immunosuppressive Agents; Lysophospholipids; Multiple Sclerosis; Receptors, Lysosphingolipid; Sphingosine 1 Phosphate Receptor Modulators; Sphingosine-1-Phosphate Receptors; Stroke | 2022 |
FTY720 (Fingolimod) Ameliorates Brain Injury through Multiple Mechanisms and is a Strong Candidate for Stroke Treatment.
Topics: Animals; Brain Injuries; Endothelial Cells; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Neural Stem Cells; Propylene Glycols; Receptors, Lysosphingolipid; Stroke | 2020 |
Repurposed molecules for antiepileptogenesis: Missing an opportunity to prevent epilepsy?
Topics: Acetylcysteine; Animals; Anticonvulsants; Antioxidants; Atorvastatin; Brain Injuries, Traumatic; Ceftriaxone; Dibenzazepines; Drug Repositioning; Epilepsy; Epilepsy, Post-Traumatic; Erythropoietin; Fingolimod Hydrochloride; GABA Agents; Gabapentin; Humans; Immunologic Factors; Inflammation; Interleukin 1 Receptor Antagonist Protein; Isoflurane; Levetiracetam; Losartan; Neuroprotective Agents; Oxidative Stress; Pregabalin; Pyrrolidinones; Sirolimus; Stroke; Topiramate; Translational Research, Biomedical; Vigabatrin | 2020 |
The emerging role of FTY720 as a sphingosine 1-phosphate analog for the treatment of ischemic stroke: The cellular and molecular mechanisms.
Topics: Animals; Brain Ischemia; Endothelial Cells; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Ischemic Stroke; Lysophospholipids; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine; Stroke | 2021 |
Systematic review and meta-analysis of the efficacy of sphingosine-1-phosphate (S1P) receptor agonist FTY720 (fingolimod) in animal models of stroke.
Topics: Animals; Disease Models, Animal; Fingolimod Hydrochloride; Humans; Propylene Glycols; Receptors, Lysosphingolipid; Recovery of Function; Sphingosine; Stroke; Treatment Outcome | 2013 |
5 trial(s) available for fingolimod hydrochloride and Apoplexy
| Article | Year |
|---|---|
Rationale and design of combination of an immune modulator Fingolimod with Alteplase bridging with Mechanical Thrombectomy in Acute Ischemic Stroke (FAMTAIS) trial.
Topics: Brain Ischemia; Combined Modality Therapy; Fibrinolytic Agents; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Mechanical Thrombolysis; Reperfusion Injury; Research Design; Stroke; Time-to-Treatment; Tissue Plasminogen Activator | 2017 |
Fingolimod enhances the efficacy of delayed alteplase administration in acute ischemic stroke by promoting anterograde reperfusion and retrograde collateral flow.
Topics: Aged; Collateral Circulation; Drug Therapy, Combination; Female; Fibrinolytic Agents; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Recovery of Function; Reperfusion; Stroke; Time-to-Treatment; Tissue Plasminogen Activator | 2018 |
Efficacy of fingolimod combined with alteplase in acute ischemic stroke and rehabilitation nursing.
Topics: Administration, Oral; Drug Administration Schedule; Drug Therapy, Combination; Female; Fibrinolytic Agents; Fingolimod Hydrochloride; Humans; Infusions, Intravenous; Lymphocytes; Magnetic Resonance Imaging; Male; Middle Aged; Stroke; Stroke Rehabilitation; Thrombolytic Therapy; Tissue Plasminogen Activator; Treatment Outcome | 2019 |
Impact of an immune modulator fingolimod on acute ischemic stroke.
Topics: Adult; Aged; Brain Ischemia; Case-Control Studies; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lymphocyte Subsets; Male; Middle Aged; Propylene Glycols; Single-Blind Method; Sphingosine; Stroke | 2014 |
Combination of the Immune Modulator Fingolimod With Alteplase in Acute Ischemic Stroke: A Pilot Trial.
Topics: B-Lymphocytes; Dose-Response Relationship, Drug; Drug Therapy, Combination; Edema, Cardiac; Female; Fibrinolytic Agents; Fingolimod Hydrochloride; Humans; Immunologic Factors; Magnetic Resonance Imaging; Male; Middle Aged; Myocardial Reperfusion Injury; Pilot Projects; Recovery of Function; Stroke; T-Lymphocytes; Tissue Plasminogen Activator; Treatment Outcome | 2015 |
12 other study(ies) available for fingolimod hydrochloride and Apoplexy
| Article | Year |
|---|---|
USPIO-SWI Shows Fingolimod Enhanced Alteplase Action on Angiographic Reperfusion in eMCAO Rats.
Topics: Animals; Contrast Media; Dextrans; Embolism; Fingolimod Hydrochloride; Infarction, Middle Cerebral Artery; Magnetic Resonance Imaging; Magnetite Nanoparticles; Mice; Rats; Reperfusion; Stroke; Tissue Plasminogen Activator | 2022 |
Fingolimod Does Not Reduce Infarction After Focal Cerebral Ischemia in Mice During Active or Inactive Circadian Phases.
Topics: Animals; Brain Edema; Brain Ischemia; Disease Models, Animal; Fingolimod Hydrochloride; Hemorrhage; Infarction, Middle Cerebral Artery; Male; Mice; Mice, Inbred C57BL; Sphingosine; Stroke | 2022 |
Role of the S1P pathway and inhibition by fingolimod in preventing hemorrhagic transformation after stroke.
Topics: Animals; Brain; Brain Ischemia; Fingolimod Hydrochloride; Hemoglobins; Hemorrhage; Lymphocytes; Lysophospholipids; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Myeloid Cells; Reperfusion Injury; RNA, Messenger; Sphingosine; Sphingosine 1 Phosphate Receptor Modulators; Sphingosine-1-Phosphate Receptors; Stroke; T-Lymphocytes; Thrombocytopenia; Up-Regulation | 2019 |
FTY720 treatment in the convalescence period improves functional recovery and reduces reactive astrogliosis in photothrombotic stroke.
Topics: Aldehyde-Lyases; Animals; Astrocytes; Cerebral Cortex; Convalescence; Fingolimod Hydrochloride; Gene Expression; Gliosis; Immunosuppressive Agents; Intracranial Thrombosis; Male; Mice; Mice, Inbred C57BL; Post-Synaptic Density; Propylene Glycols; Recovery of Function; Reverse Transcriptase Polymerase Chain Reaction; Sphingosine; Stroke; Time Factors; Treatment Outcome; Vascular Endothelial Growth Factor A | 2013 |
FTY720 ameliorates acute ischemic stroke in mice by reducing thrombo-inflammation but not by direct neuroprotection.
Topics: Animals; Brain Ischemia; Enzyme Inhibitors; Fingolimod Hydrochloride; Homeodomain Proteins; Hypoxia; Immunosuppressive Agents; Inflammation; Lymphocytes; Lymphopenia; Male; Mice; Mice, Transgenic; Middle Cerebral Artery; Neurons; Neuroprotective Agents; Propylene Glycols; Sphingosine; Stroke; Thrombosis | 2013 |
Exogenous S1P Exposure Potentiates Ischemic Stroke Damage That Is Reduced Possibly by Inhibiting S1P Receptor Signaling.
Topics: Animals; Blood-Brain Barrier; Brain Ischemia; Fingolimod Hydrochloride; Lysophospholipids; Male; Mice; Mice, Inbred ICR; Microinjections; Neuroglia; Phosphotransferases (Alcohol Group Acceptor); Receptors, Lysosphingolipid; Signal Transduction; Sphingosine; Stroke; Tumor Necrosis Factor-alpha | 2015 |
Fingolimod (FTY720) Reduces Cortical Infarction and Neurological Deficits During Ischemic Stroke Through Potential Maintenance of Microvascular Patency.
Topics: Animals; Brain; Brain Infarction; Brain Ischemia; Brain-Derived Neurotrophic Factor; Disease Models, Animal; Fingolimod Hydrochloride; Infarction, Middle Cerebral Artery; Male; Mice, Inbred C57BL; Microvessels; Stroke | 2016 |
Activation of sphingosine 1-phosphate receptor-1 by FTY720 is neuroprotective after ischemic stroke in rats.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Brain; Brain Ischemia; Disease Models, Animal; Drug Administration Schedule; Fingolimod Hydrochloride; Immunosuppressive Agents; In Situ Nick-End Labeling; Infarction, Middle Cerebral Artery; Male; MAP Kinase Signaling System; Nerve Degeneration; Neuroprotective Agents; Oxadiazoles; Propylene Glycols; Rats; Rats, Sprague-Dawley; Receptors, Lysosphingolipid; Sphingosine; Stroke; Thiophenes; Treatment Outcome | 2010 |
Targeting the sphingolipid signaling pathway in stroke.
Topics: Animals; Blood-Brain Barrier; Clinical Trials as Topic; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Neuroprotective Agents; Propylene Glycols; Rats; Receptors, Lysosphingolipid; Signal Transduction; Sphingolipids; Sphingosine; Stroke | 2010 |
Fingolimod provides long-term protection in rodent models of cerebral ischemia.
Topics: Animals; Apoptosis; Brain Ischemia; Disease Models, Animal; Fingolimod Hydrochloride; Immunosuppressive Agents; In Vitro Techniques; Inflammation; Mice; Mice, Inbred C57BL; Neurons; Neuroprotective Agents; Neurotoxicity Syndromes; Propylene Glycols; Rats; Receptors, Lysosphingolipid; Sphingosine; Stroke | 2011 |
[Neurology].
Topics: Antibodies, Monoclonal; Anticonvulsants; Atrial Fibrillation; Carbamates; Chronic Disease; Deep Brain Stimulation; Dopamine Agonists; Epilepsy; Fingolimod Hydrochloride; Genetic Therapy; Humans; Immunosuppressive Agents; Ischemic Attack, Transient; Multiple Sclerosis; Muscular Diseases; Neurology; Parkinson Disease; Phenylenediamines; Polyneuropathies; Propylene Glycols; Sphingosine; Stroke; Treatment Outcome; Valproic Acid | 2012 |
The safety risks of innovation: the FDA's Expedited Drug Development Pathway.
Topics: Anticoagulants; Antineoplastic Agents; Benzimidazoles; beta-Alanine; Carcinoma, Neuroendocrine; Clinical Trials as Topic; Dabigatran; Drug Approval; Efficiency, Organizational; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Patient Safety; Piperidines; Propylene Glycols; Quinazolines; Risk; Sphingosine; Stroke; Thyroid Neoplasms; Time Factors; United States; United States Food and Drug Administration | 2012 |